# Benign Prostatic Hypertrophy Treatment Patterns & Outcomes: Marketscan

> **NCT01323998** · — · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 35032 (actual)

## Conditions studied

- Prostatic Hyperplasia

## Interventions

- **DRUG:** 5ARI
- **DRUG:** AB

## Key facts

- **NCT ID:** NCT01323998
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2010-04
- **Primary completion:** 2010-06
- **Final completion:** 2010-06
- **Target enrollment:** 35032 (ACTUAL)
- **Last updated:** 2017-07-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01323998

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01323998, "Benign Prostatic Hypertrophy Treatment Patterns & Outcomes: Marketscan". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01323998. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*